Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.48 |
| ▸ | LATS1 | O95835 | 7/20 | 0.41 |
| ▸ | LATS2 | Q9NRM7 | 5/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460906 | 0.86 | GBA1 (0.51) | GBA1LATS1LATS2 | |
| SCHEMBL3459386 | 0.85 | GBA1 (0.66) | GBA1ABCG2LATS1LATS2ABCB1 | |
| SCHEMBL3460107 | 0.85 | GBA1 (0.66) | GBA1ABCG2LATS1LATS2ABCB1 | |
| SCHEMBL3459802 | 0.83 | GBA1 (0.40) | GBA1ABCG2RORCCHEK1CHEK2 | |
| SCHEMBL3459495 | 0.81 | GBA1 (0.52) | GBA1ABCG2LATS1LATS2 | |
| SCHEMBL3460210 | 0.80 | WHR1 (0.48) | GBA1ABCG2LATS1LATS2CHEK1 | |
| SCHEMBL3459580 | 0.80 | GBA1 (0.51) | GBA1ABCG2LATS1LATS2 | |
| SCHEMBL3459779 | 0.79 | GBA1 (0.63) | GBA1ABCG2 | |
| SCHEMBL3459952 | 0.79 | GBA1 (0.63) | GBA1ABCG2 | |
| SCHEMBL3460116 | 0.75 | GBA1 (0.68) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | claimed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | claimed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161651-A1 | Tie-2 modulators and methods of use | TIE1, TEK, KDR | GBA1 4763/4885ABCG2 2700/4885LATS1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.